Postoperative Benefits of Cilostazol on Patients Undergoing Intervention for Chronic Limb Ischemia

Although prior studies have shown the short-term benefits of cilostazol on claudicant patients who underwent iliac or femoropopliteal revascularization procedures, the literature on patients with chronic limb ischemia (CLI) is limited. Recent molecular analysis suggests that the possible cardiovascular benefits of cilostazol are mediated through a nitric oxide pathway. As such, we hypothesized that cilostazol use in patients undergoing intervention for CLI would have reduced major adverse limb events, reinterventions, and improved long-term survival.

Source: Journal of Vascular Surgery - May 23, 2023 Category: Surgery Authors: Jose Antonio Munoz, Alexandra A. Sansosti, Yaagnik Kosuri, Danielle Bajakian, Nicholas Morrissey, Karan Garg, Jeffrey J. Siracuse, Jessica Ding, Abhishek Rao, Katharina Horn, Priya B. Patel, Thomas F.X. O'Donnell, Virendra I. Patel Tags: Poster Competition Source Type: research